Collectively, this demonstrates that Ref-1/APE1 plays a vital role in NSCLC progression, and targeting it might lead to better patient outcomes when combined with various chemotherapeutic treatments. The gene discussed is APEX1; the disease is non-small cell lung carcinoma.